OKYO Pharma CEO Announces First Dosing in Phase 2 Trial for OK-101 to Treat Neuropathic Corneal Pain

By Proactive Investors / October 24, 2024 / www.youtube.com / Article Link


OKYO Pharma CEO Gary Jacob joined Steve Darling from Proactive to share news the company is reporting the first patient has ...

Recent News

Geopolitical risk outlook unclear after US election

January 06, 2025 / www.canadianminingreport.com

Low valuations offer a cushion to mining sector

January 06, 2025 / www.canadianminingreport.com

Polarized gold and iron ore moves, moderate aluminum and copper gains

December 30, 2024 / www.canadianminingreport.com

Large TSXV stocks strong on company specific drivers

December 30, 2024 / www.canadianminingreport.com

Canadian political turmoil with Trump trade policy the catalyst

December 23, 2024 / www.canadianminingreport.com
See all >
Share to Youtube Share to Facebook Facebook Share to Linkedin Share to Twitter Twitter Share to Tiktok